文献速递肿瘤 PET/CT

18F-FDG PET/CT在68Ga-PSMA阴性生化复发前列腺癌中的诊断价值

Diagnostic value of 18F-FDG PET/CT in patients with biochemical recurrent prostate cancer and negative 68Ga-PSMA PET/CT.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-02-02

该回顾性研究纳入72例68Ga-PSMA PET/CT阴性的生化复发前列腺癌患者,评估18F-FDG PET/CT的检出率及预测因素。18F-FDG检出率为16.7%(12/72),PSA≥2.3 ng/mL和Gleason评分≥8是18F-FDG阳性的独立预测因素,高潜力组阳性概率达90.0%。

要点

  • 68Ga-PSMA阴性BCR患者中18F-FDG PET/CT检出率为16.7%。
  • PSA≥2.3 ng/mL和Gleason评分≥8与18F-FDG阳性独立相关。
  • 高潜力组(PSA≥2.3且Gleason≥8)18F-FDG阳性概率为90.0%。

核心结论

  • PSA水平和Gleason评分是18F-FDG阳性的独立预测因素,68Ga-PSMA阴性且高PSA、高Gleason评分的BCR患者最可能从18F-FDG PET/CT获益。

研究设计与样本

  • 回顾性研究,从2018年6月至2020年8月间同时接受68Ga-PSMA和18F-FDG PET/CT的510例患者中,纳入72例68Ga-PSMA PET/CT阴性的生化复发前列腺癌患者。

主要发现

  • 18F-FDG PET/CT在68Ga-PSMA阴性BCR患者中的检出率为16.7%(12/72)。
  • 18F-FDG阳性组PSA和Gleason评分均显著高于阴性组(P < 0.001和P < 0.001)。
  • 多因素分析显示PSA≥2.3 ng/mL和Gleason评分≥8与18F-FDG阳性相关(P < 0.001和P = 0.015)。
  • 低潜力组(PSA<2.3 ng/mL且Gleason<8)、中潜力组(PSA<2.3 ng/mL且Gleason≥8或PSA≥2.3 ng/mL且Gleason<8)和高潜力组(PSA≥2.3 ng/mL且Gleason≥8)的18F-FDG阳性概率分别为0%、11.5%和90.0%(P < 0.001)。

关键数值与推荐

  • PSA≥2.3 ng/mL和Gleason评分≥8是18F-FDG阳性的预测阈值。
  • 高潜力组(PSA≥2.3 ng/mL且Gleason评分≥8)18F-FDG阳性概率为90.0%。

临床怎么用

  • 对于68Ga-PSMA PET/CT阴性的生化复发前列腺癌患者,若PSA≥2.3 ng/mL且Gleason评分≥8,可考虑追加18F-FDG PET/CT以提高病灶检出。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: 68Ga-PSMA PET/CT has a high detection rate in prostate cancer patients with biochemical recurrence (BCR). However, few studies have reported other imaging methods for BCR with negative 68Ga-PSMA PET/CT findings. We investigated the value of 18F-FDG compared with 68Ga-PSMA and identified BCR patients with 68Ga-PSMA-negative findings who are most likely to benefit from 18F-FDG PET/CT. METHODS: Seventy-two BCR patients with negative 68Ga-PSMA PET/CT findings were retrospectively identified from 510 patients who underwent concomitant 68Ga-PSMA and 18F-FDG PET/CT between June 2018 and August 2020. Patients were categorised into groups with positive or negative 18F-FDG PET/CT findings. Differences in patients' characteristics between these two groups and predictors of positive 18F-FDG findings were analysed. RESULTS: The detection rate of 18F-FDG PET/CT was 16.7% (12/72) in BCR patients with 68Ga-PSMA-negative findings. PSA and Gleason score were significantly higher in the 18F-FDG-positive group than in the 18F-FDG-negative group (P < 0.001 and P < 0.001, respectively). A multivariate analysis indicated that PSA (PSA ≥2.3 ng/mL) and Gleason score (Gleason score ≥ 8) correlated with 18F-FDG-positive findings (P < 0.001 and P = 0.015, respectively). The probabilities of 18F-FDG-positive findings in the low-potential (PSA <2.3 ng/mL and Gleason score <8), moderate-potential (PSA <2.3 ng/mL and Gleason score ≥ 8 or PSA ≥2.3 ng/mL and Gleason score <8), and high-potential (PSA ≥2.3 ng/mL and Gleason score ≥ 8) groups were 0%, 11.5%, and 90.0%, respectively (P < 0.001). CONCLUSION: PSA level and Gleason score are independent predictors of 18F-FDG-positive findings, and BCR patients with 68Ga-PSMA-negative findings with high PSA and Gleason score are most likely to benefit from 18F-FDG PET/CT.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Chen R, Wang Y, Shi Y, et al. Diagnostic value of 18F-FDG PET/CT in patients with biochemical recurrent prostate cancer and negative 68Ga-PSMA PET/CT. Eur J Nucl Med Mol Imaging. 2021. PMID: 33528607. doi:10.1007/s00259-021-05221-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。